The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A pilot study of the neoadjuvant use of vemurafenib plus cobimetinib in patients with BRAF-mutant melanoma with palpable lymph node metastases: Survival results.
 
Teresa M. Petrella
Honoraria - AstraZeneca; EMD Serono; Merck; Novartis; Sanofi
Consulting or Advisory Role - AstraZeneca; EMD Serono; Merck; Novartis; Sanofi
Speakers' Bureau - AstraZeneca; EMD Serono; Merck; Novartis; Sanofi
 
Catalin Liviu Dragos Mihalcioiu
Consulting or Advisory Role - BMS; Merck; Novartis; Pfizer
Research Funding - BMS; Incyte (Inst); Merck; Pfizer; Pfizer (Inst); Precirix (Inst)
Travel, Accommodations, Expenses - Novartis
 
Carolyn Nessim
No Relationships to Disclose
 
Alan Spatz
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; Merck; Novartis; Pfizer/EMD Serono; Roche
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
 
Ian Watson
Consulting or Advisory Role - DROIA; METIS therapeutics
Research Funding - Pfizer
 
Frances Catriona Wright
Honoraria - BMS; Merck
Research Funding - Roche (Inst)